MeiraGTx Holdings Plc (MGTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH2488361D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

October 2018

Total pages

31

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

MeiraGTx Holdings Plc (MeiraGTx) is an independent clinical-stage gene therapy company that focuses on the development of therapeutics for the treatment of eye, salivary gland and neurodegenerative diseases. The company's pipeline of preclinical and research programs include AAV-CNGB3, for achromatopsia; AAV-RPGR, for X-linked retinitis pigmentosa; AAV-RPE65, for RPE65-Deficiency; AAV-AQP1, for xerostomia and sjogren's syndrome; and AAV-UPF1, for amyotrophic lateral sclerosis (ALS) among others. MeiraGTx works in collaboration with leading institutions to develop next-generation gene therapies. The company has presence in the US, the UK and the Netherlands. MeiraGTx is headquartered in New York, the US.

MeiraGTx Holdings Plc (MGTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

MeiraGTx Holdings Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 10

MeiraGTx and eXmoor pharma Enter into Agreement 11

Oxford Genetics Enters into Agreement with MeiraGTx 12

MeiraGTx Enters into Agreement with Weill Cornell Medicine 13

MeiraGTx Enters into Agreement with Weill Cornell Medicine and LSU Health Shreveport 14

Athena Vision Enters into Agreement with MeiraGTx 15

Licensing Agreements 16

MeiraGTx Enters into Licensing Agreement with UCL Business 16

MeiraGTx Enters into Licensing Agreement with UCL Business 17

Equity Offering 18

MeiraGTx Raises USD75 Million in IPO of Shares 18

Acquisition 19

MeiraGTx Acquires Vector Neurosciences 19

MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 20

MeiraGTx Holdings Plc-Key Competitors 21

MeiraGTx Holdings Plc-Key Employees 22

MeiraGTx Holdings Plc-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Legal and Regulatory 24

Jun 21, 2018: MeiraGTx Announces MHRA Grants MIA (IMP) License for cGMP Manufacturing Facility in London, UK 24

Government and Public Interest 25

Feb 01, 2017: MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALS 25

Product News 26

08/24/2017: MeiraGTx Provides Clinical Trial Update for Leber Congenital Amaurosis Type 2 Gene Therapy Program 26

Product Approvals 27

Dec 07, 2017: MeiraGTx Receives Rare Pediatric Disease Designation for A001 for the Treatment of Leber's Congenital Amaurosis and Treats First Pediatric Patient in Phase I/II Clinical Trial 27

Clinical Trials 28

Oct 17, 2017: MeiraGTx Presents Preclinical Data on AAV2/5-OPTIRPE65 for the Treatment of Lebers Congenital Amaurosis at ESGCT 2017 Congress in Berlin 28

Aug 24, 2017: MeiraGTx Provides Clinical Trial Update for Achromatopsia Gene Therapy Program 29

Aug 24, 2017: MeiraGTx Provides Clinical Trial Update for X-Linked Retinitis Pigmentosa Gene Therapy Program 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List of Figure

List of Figures

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List of Table

List of Tables

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

MeiraGTx Holdings Plc, Deals By Therapy Area, 2012 to YTD 2018 8

MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 10

MeiraGTx and eXmoor pharma Enter into Agreement 11

Oxford Genetics Enters into Agreement with MeiraGTx 12

MeiraGTx Enters into Agreement with Weill Cornell Medicine 13

MeiraGTx Enters into Agreement with Weill Cornell Medicine and LSU Health Shreveport 14

Athena Vision Enters into Agreement with MeiraGTx 15

MeiraGTx Enters into Licensing Agreement with UCL Business 16

MeiraGTx Enters into Licensing Agreement with UCL Business 17

MeiraGTx Raises USD75 Million in IPO of Shares 18

MeiraGTx Acquires Vector Neurosciences 19

MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 20

MeiraGTx Holdings Plc, Key Competitors 21

MeiraGTx Holdings Plc, Key Employees 22

MeiraGTx Holdings Plc, Subsidiaries 23

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022